Merck & Co. Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Merck & Co. (MRK) shares fell 2.15% to $126.78 on Monday, underperforming the broader market as the S&P 500 and Dow Jones rose. The stock closed 2.69% below its 52-week high of $130.29. Trading volume was lower than the 50-day average. Compared to competitors, Merck's decline was steeper than Johnson & Johnson and Eli Lilly but milder than Pfizer.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Merck & Co. Inc. (MRK) shed 2.15% to $126.78 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.72% to 7,537.43 and the Dow Jones Industrial Average rising 0.29% to 53,055.91.
Merck & Co. Inc. closed 2.69% short of its 52-week high of $130.29, which the company reached on June 30th.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) fell 1.41% to $259.33, Pfizer Inc. (PFE) fell 2.47% to $23.72, and Eli Lilly & Co. (LLY) fell 1.14% to $1,200.06.
Trading volume (9.2 M) remained 1.4 million below its 50-day average volume of 10.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 6, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-06-26 1633ET